Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar ZiextenzoTM (pegfilgrastim-bmez)

  • Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy
     
  • With approval of Ziextenzo™ , Sandoz is first and only company to offer US physicians long- and short-acting filgrastim biosimilar treatment options
     
  • With four US approved biosimilars, Sandoz is committed to expanding patient access, increasing healthcare savings and fueling innovation

Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global …

/by

Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US

  • Continuing operations2 net sales up 13% (cc1, +10% USD) driven by:
    • Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regions
    • Entresto USD 430 million (+61% cc), with increased demand in hospital and ambulatory settings
    • Zolgensma sales of USD 160 million, strong launch including broad access
    • Lutathera sales grew to USD 119 million, total AAA sales were USD 177 million
    • Piqray sales were USD 43 million, off to a strong start …
/by

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

  • Worldwide agreement with Polpharma Biologics gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS)
  • RRMS affects ~85% of MS patients and can create a substantial social and economic burden on patients, their families and healthcare systems[1],[2]
  • Natalizumab is fifth proposed biosimilar in-licensed by Sandoz in nine months, underscoring commitment to further grow pipeline through collaborations

Holzkirchen, Germany, September 3, 2019 …

/by

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case

  • Sandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit
  • Ruling prevents launch of important, affordable treatment option for US patients affected by chronic autoimmune and inflammatory diseases
  • Sandoz remains deeply committed to providing Erelzi® as soon as possible, contributing to a more sustainable healthcare system

Holzkirchen, Germany, 9 August 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States …

/by

Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis

  • Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] 
  • Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures — number set to increase substantially over next two decades[2]
  • Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab

Holzkirchen, July 22, 2019 – Sandoz, a Novartis division and a global leader in …

/by

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

  • Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by:
    • Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%)
    • Entresto grew to USD 421 million, +81% (cc) with increased initiation in hospital and ambulatory settings
    • Oncology sales grew 9% (cc) driven by growth from Lutathera (USD 109 million), Kisqali (USD 111 million) and Kymriah (USD 58 million) in the second quarter
    • Sandoz sales grew 3% (cc, -1% USD) as ex-US growth more than …
/by

Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine

  • Adult and pediatric doses immediately available as single-dose, pre-filled syringe and device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis1
  • SYMJEPI will help address critical impact of ongoing epinephrine auto-injector shortages2 for the one in 50 Americans at risk for anaphylaxis3
  • Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need

Princeton, New …

/by

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

  • Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1]
  • More than 300,000 European men and women are diagnosed with lung cancer annually, making it the fourth most common cancer[2]
  • With launch Sandoz builds on robust 50+ medicine oncology portfolio globally, including chemotherapy, targeted therapy, hormones and supportive care[3]

Holzkirchen, Germany, July 2, 2019 – Sandoz today announced the launch of the generic …

/by